Paul  Bolno net worth and biography

Paul Bolno Biography and Net Worth

Dr. Paul Bolno has served as President and CEO of Wave since 2013 and oversaw the company’s initial public offering in 2015. During his tenure as President and CEO, Paul has grown Wave into a leading RNA medicines company, overseen the development of the company’s proprietary PRISM® platform, and built a diversified pipeline of preclinical and clinical programs supported by scalable, in-house manufacturing capabilities.

In addition to his current role at Wave, Paul serves as Chairman of the Board of Directors to ExpressionEdits, and as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom.

Prior to joining Wave, he was Vice President, Worldwide Business Development—Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline (GSK). He also served as a Director of Glaxo Wellcome Manufacturing, Pte Ltd. in Singapore. Paul joined GSK as Vice President, Business Development for the Oncology Business Unit, where he helped establish GSK’s global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GSK, he served as Director of Research at Two River LLC, a healthcare private equity firm.

Paul earned a medical degree from MCP-Hahnemann School of Medicine and an MBA from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.

What is Paul Bolno's net worth?

The estimated net worth of Paul Bolno is at least $1.98 million as of March 7th, 2025. Bolno owns 338,351 shares of Wave Life Sciences stock worth more than $1,975,970 as of April 17th. This net worth evaluation does not reflect any other investments that Bolno may own. Additionally, Bolno receives a salary of $1,130,000.00 as CEO at Wave Life Sciences. Learn More about Paul Bolno's net worth.

How old is Paul Bolno?

Bolno is currently 50 years old. There are 3 older executives and no younger executives at Wave Life Sciences. Learn More on Paul Bolno's age.

What is Paul Bolno's salary?

As the CEO of Wave Life Sciences Ltd., Bolno earns $1,130,000.00 per year. Learn More on Paul Bolno's salary.

How do I contact Paul Bolno?

The corporate mailing address for Bolno and other Wave Life Sciences executives is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. Wave Life Sciences can also be reached via phone at (656) 236-3388 and via email at krausch@wavelifesci.com. Learn More on Paul Bolno's contact information.

Has Paul Bolno been buying or selling shares of Wave Life Sciences?

Paul Bolno has not been actively trading shares of Wave Life Sciences during the last quarter. Most recently, Paul Bolno sold 169,025 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $9.57, for a transaction totalling $1,617,569.25. Following the completion of the sale, the chief executive officer now directly owns 338,351 shares of the company's stock, valued at $3,238,019.07. Learn More on Paul Bolno's trading history.

Who are Wave Life Sciences' active insiders?

Wave Life Sciences' insider roster includes Paul Bolno (CEO), Chris Francis (insider), Christian Henry (Director), and Kyle Moran (CFO). Learn More on Wave Life Sciences' active insiders.

Are insiders buying or selling shares of Wave Life Sciences?

In the last twelve months, Wave Life Sciences insiders bought shares 1 times. They purchased a total of 2,791,930 shares worth more than $22,335,440.00. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 681,581 shares worth more than $8,425,592.73. The most recent insider tranaction occured on March, 20th when Director Christian O Henry sold 10,500 shares worth more than $102,585.00. Insiders at Wave Life Sciences own 29.1% of the company. Learn More about insider trades at Wave Life Sciences.

Information on this page was last updated on 3/20/2025.

Paul Bolno Insider Trading History at Wave Life Sciences

See Full Table

Paul Bolno Buying and Selling Activity at Wave Life Sciences

This chart shows Paul Bolno's buying and selling at Wave Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Wave Life Sciences Company Overview

Wave Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $5.84
Low: $5.75
High: $6.23

50 Day Range

MA: $9.10
Low: $5.48
High: $11.33

2 Week Range

Now: $5.84
Low: $4.25
High: $16.74

Volume

993,878 shs

Average Volume

1,182,470 shs

Market Capitalization

$896.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A